These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 32615709)

  • 1. Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease.
    Lee DH
    Endocrinol Metab (Seoul); 2020 Jun; 35(2):243-259. PubMed ID: 32615709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
    Castera L; Friedrich-Rust M; Loomba R
    Gastroenterology; 2019 Apr; 156(5):1264-1281.e4. PubMed ID: 30660725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
    Zhou JH; Cai JJ; She ZG; Li HL
    World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications.
    Hydes T; Brown E; Hamid A; Bateman AC; Cuthbertson DJ
    Clin Ther; 2021 Sep; 43(9):1505-1522. PubMed ID: 34400007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Sumida Y; Nakajima A; Itoh Y
    World J Gastroenterol; 2014 Jan; 20(2):475-85. PubMed ID: 24574716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.
    Tsai E; Lee TP
    Clin Liver Dis; 2018 Feb; 22(1):73-92. PubMed ID: 29128062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to Diagnose Nonalcoholic Fatty Liver Disease.
    de Alwis NM; Anstee QM; Day CP
    Dig Dis; 2016; 34 Suppl 1():19-26. PubMed ID: 27547937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts.
    Papatheodoridi M; Cholongitas E
    Curr Pharm Des; 2018; 24(38):4574-4586. PubMed ID: 30652642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninvasive evaluation of NAFLD.
    Castera L; Vilgrain V; Angulo P
    Nat Rev Gastroenterol Hepatol; 2013 Nov; 10(11):666-75. PubMed ID: 24061203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis.
    Golabi P; Sayiner M; Fazel Y; Koenig A; Henry L; Younossi ZM
    Expert Rev Gastroenterol Hepatol; 2016; 10(1):63-71. PubMed ID: 26469309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in noninvasive methods for diagnosing nonalcoholic fatty liver disease.
    Shen FF; Lu LG
    J Dig Dis; 2016 Sep; 17(9):565-571. PubMed ID: 27429213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
    Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
    United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Noninvasive Tests for Differentiating NASH From NAFL and Diagnosing Advanced Fibrosis Among Patients With NAFLD.
    Balakrishnan M; Loomba R
    J Clin Gastroenterol; 2020 Feb; 54(2):107-113. PubMed ID: 31789757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods.
    Yoneda M; Imajo K; Takahashi H; Ogawa Y; Eguchi Y; Sumida Y; Yoneda M; Kawanaka M; Saito S; Tokushige K; Nakajima A
    J Gastroenterol; 2018 Feb; 53(2):181-196. PubMed ID: 29177681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiologic evaluation of nonalcoholic fatty liver disease.
    Lee SS; Park SH
    World J Gastroenterol; 2014 Jun; 20(23):7392-402. PubMed ID: 24966609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive biomarkers in NAFLD and NASH - current progress and future promise.
    Wong VW; Adams LA; de Lédinghen V; Wong GL; Sookoian S
    Nat Rev Gastroenterol Hepatol; 2018 Aug; 15(8):461-478. PubMed ID: 29844588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease.
    Costa-Silva L; Ferolla SM; Lima AS; Vidigal PVT; Ferrari TCA
    Eur J Radiol; 2018 Jan; 98():82-89. PubMed ID: 29279175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of Ultrasound and Shear Wave Elastography Imaging in a Rat Model of NAFLD/NASH.
    Morin J; Swanson TA; Rinaldi A; Boucher M; Ross T; Hirenallur-Shanthappa D
    J Vis Exp; 2021 Apr; (170):. PubMed ID: 33970131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: new trends and role of ultrasonography.
    Tada T; Nishimura T; Yoshida M; Iijima H
    J Med Ultrason (2001); 2020 Oct; 47(4):511-520. PubMed ID: 33089412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?
    Alkhouri N; Feldstein AE
    Metabolism; 2016 Aug; 65(8):1087-95. PubMed ID: 26972222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.